IF-MCT 16:8: Investigating the Influence of Intermittent Fasting With and Without MCTs in Patients With Drug-resistant Epilepsy

Launched by UNIVERSITY HOSPITAL MARBURG · Aug 24, 2023

Keywords

ClinConnect Summary

The clinical trial titled "IF-MCT 16:8" is studying how a specific eating pattern called intermittent fasting, with or without the addition of a type of fat called medium chain triglycerides (MCTs), can affect the number of seizures in people with epilepsy that doesn’t respond to standard treatments. In this trial, participants will follow an intermittent fasting plan for 12 weeks. Some will take MCTs daily, while others will not, to see how both methods compare in reducing seizures.

To be eligible for this study, participants should be between the ages of 65 and 74, have epilepsy that has not been well controlled by medication, and experience at least three seizures each month. Unfortunately, individuals who are pregnant, breastfeeding, or have certain health conditions like diabetes or chronic gut diseases cannot participate. If you join the trial, you’ll be monitored closely for 12 weeks as researchers evaluate how these dietary changes impact your condition. This trial is currently recruiting participants, so if you or someone you know might be interested, it’s a good opportunity to help advance research in epilepsy treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects able to provide informed consent
• • Drug-resistant epilepsy
• • At least 3 seizures per month
• Exclusion Criteria:
• • Pregnancy
• • Breast feeding period
• • Metabolic disorder (e.g. diabetes, liver cirrhosis, kidney disease)
• • Eating Disorder (e.g. anorexia, bulimia)
• • Chronic inflammatory gut disease
• • Active cancerous disease
• • Antibiotics within the last 3 months